在轴性脊柱关节炎患者中增强了1型干扰素信号,这些患者对secukinumab治疗没有反应
Addison Pacheco1, Sinead Maguire2, Zoya Qaiyum3
1Schroeder Arthritis Institute, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Arthritis & rheumatology (Hoboken, N.J.)
|August 20, 2024
概括
轴性脊椎关节炎 (axSpA) 患者对secukinumab治疗没有反应,具有不同的免疫特征. 没有反应的人表现出更高的IL-17A产生细胞和1型干扰素特征,表明炎症更大.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 炎症性疾病 炎症性疾病
背景情况:
- 轴性脊椎关节炎 (axSpA) 的特征是由交联素-17A (IL-17A) 驱动的炎症.
- 一种针对IL-17A的生物药物Secukinumab在许多axSpA患者中改善了结果.
- 了解对secukinumab的不反应对于个性化治疗策略至关重要.
研究的目的:
- 在axSpA.中区分secukinumab响应者 (SEC-R) 和不响应者 (SEC-NR) 之间的免疫特征.
- 在 axSpA.中识别与治疗反应相关的免疫生物标志物.
- 探索 axSpA.中的免疫反应的异质性.
主要方法:
- 从30名axSpA患者的外周血液单核细胞在24周治疗sequukinumab之前和之后进行了分析.
- 使用流细胞计量来比较SEC-R和SEC-NR组之间的CD4+T细胞子集频率.
- 对排序的CD4+T细胞进行了RNA分析 (纳米链),以评估基因表达.
主要成果:
- 与健康对照组相比,没有反应者 (SEC-NR) 呈现出更高的IL-17A产生RORγt+CD4+T细胞的频率.
- 与SEC-R患者相比,SEC-NR患者在治疗前具有显著更多的CXCR3+ CD4+ T细胞.
- SEC-NR患者在治疗后表现出1型干扰素 (IFN) 调节的基因表达增加,而SEC-R患者在治疗前表现出高调节的细胞毒性CD4+T细胞基因特征.
结论:
- 在SEC-NR患者中,IL-17A产生细胞的增加表明基线炎症负担较高.
- 在治疗后的SEC-NR患者中,明显的1型IFN特征可能会导致他们的炎症负担.
- AxSpA表现出显著的免疫异质性,需要精确的治疗方法.
更多相关视频
相关概念视频
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
T Cell Types and Functions
964
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
964
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120


